Rallybio Corporation
NASDAQ: RLYB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Uden
- Employees
- 15
- Headquarters
- New Haven, United States
- IPO year
- 2021
- Market cap
- $92.3M
- Website
- https://www.rallybio.com
Loading RLYB…
Loading profile data…Frequently asked questions about RLYB
What does Rallybio Corporation (RLYB) do?
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with...
Where does RLYB trade?
Rallybio Corporation (RLYB) trades on the NASDAQ Capital Market.
What sector is RLYB in?
Rallybio Corporation (RLYB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rallybio Corporation?
Stephen Uden is the chief executive officer of Rallybio Corporation (RLYB).
Where is Rallybio Corporation headquartered?
Rallybio Corporation is headquartered in United States.
Does RLYB pay a dividend?
Rallybio Corporation (RLYB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RLYB go public?
Rallybio Corporation (RLYB) completed its initial public offering in 2021.